<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00617747</url>
  </required_header>
  <id_info>
    <org_study_id>311CUS/0022</org_study_id>
    <secondary_id>D1221L00001</secondary_id>
    <nct_id>NCT00617747</nct_id>
  </id_info>
  <brief_title>Efficacy and Tolerability of Zolmitriptan Nasal Spray</brief_title>
  <official_title>A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel Group Trial to Evaluate Early Efficacy and Tolerability of Zolmitriptan (ZOMIG) Nasal Spray in the Acute Treatment of Adult Subjects With Migraine.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effectiveness and tolerability (the ability not
      to experience ill effects from the study drug) of a zolmitriptan nasal spray, 5.0 mg,
      compared with placebo (inactive drug) for 2 migraine headaches for up to 12 weeks in adult
      subjects with migraine headaches
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2002</start_date>
  <completion_date type="Actual">June 2003</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in migraine headache pain from severe or moderate to mild or none</measure>
    <time_frame>15 minutes after the initial dose of trial treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Headache response rate</measure>
    <time_frame>30 minutes and 1, 2 and 4 hours after dosing</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2114</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zolmitriptan</intervention_name>
    <description>5mg Nasal Spray</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Zomig</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has an established diagnosis of migraine headache, with or without aura

          -  Subject has a medical history indicating the presence of migraine attacks for at least
             1 year before the start of the trial or a minimum of 2 and maximum of 6 migraine
             attacks per month on average for 3 months preceding the study

          -  Subject has non migraine headaches on fewer than 6 days each month for 3 months
             preceding the study

        Exclusion Criteria:

          -  Subject has history of basilar, ophthalmoplegic or hemiplegic migraine or serious
             neurologic condition associated with headache

          -  Subject has used a MAOI within 2 weeks of randomisation or has been given SSRI therapy
             or migraine prophylactic agent within 3 months of randomisation. Subject requires
             treatment with propranolol or cimetidine or has had an intolerable or serious adverse
             event while using another triptan

          -  Subject has a history or symptoms suggestive of ischemic heart disease, coronary
             artery vasospasm or other significant underlying cardiovascular disease or clinically
             significant abnormalities seen on an ECG or uncontrolled hypertension
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 6, 2008</study_first_submitted>
  <study_first_submitted_qc>February 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2008</study_first_posted>
  <last_update_submitted>April 3, 2009</last_update_submitted>
  <last_update_submitted_qc>April 3, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 6, 2009</last_update_posted>
  <keyword>Zolmitriptan</keyword>
  <keyword>ZOMIG</keyword>
  <keyword>migraine</keyword>
  <keyword>headache response</keyword>
  <keyword>headache</keyword>
  <keyword>headache pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zolmitriptan</mesh_term>
    <mesh_term>Oxazolidinones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

